Tag Archives: Merck & Co.

Healthcare stocks roar back after slump, while biotech IPOs continue stampede into pipeline.

The News: Rising healthcare stocks and fading qualms over an escalating Syrian conflict had Wall St. optimistic to start the week. Stocks had ended lower on Friday (April 13, 2018)… Read more »

Update: CDC data say docs still making billions from Pharma, med device companies; my personal take.

The News: It’s been a few years since the US government unveiled its Open Payments (OP) database, a collection of drug and device makers’ payments to healthcare providers. The data-collection… Read more »

Merck’s Keytruda aces another cancer trial as results dazzle researchers

The News: Hot on the heels of the final presentation at ASCO’s 4-day conference in Chicago, a small, new study is causing jaws to drop after it found that a… Read more »

ASCO, aka The Oncology Super Bowl for Biotechs, sends stocks in every direction

Steve’s Take: As another jam-packed annual meeting of the American Society of Clinical Oncology in Chicago wrapped up on Tuesday (June 6, 2017), with some 38,000 oncologists gathering together at… Read more »

Amgen’s osteoporosis med almost a home run in latest trial; fate now murky on heart safety

The News: Amgen Inc. (Thousand Oaks CA) and UCB SA (Brussels) no longer expect their experimental osteoporosis drug to win US approval this year after a higher rate of serious… Read more »

Merck’s Keytruda gets chemo-combo approval for lung cancer; science, stars align for multi-billion medicine

The News: Merck & Co. announced Wednesday (May 10, 2017) that the FDA awarded accelerated approval to Keytruda (pembrolizumab), in combination with Eli Lilly & Co.’s chemotherapy regimen Alimta (pemetrexed)… Read more »

After Trump’s charge of “getting away with murder,” J&J, other Pharmas scramble to tout price restraints; but who’s kidding whom?

Steve’s Take: I thought the pharma business, like any other, was built on the bedrock precept of: charge what the market will bear, until you’re forced to pull back the… Read more »

Trump and pharma execs make nice; what, Sen. Sanders too?

The News: Last week (January 30, 2017), President Trump promised some of the nation’s top drug-company executives in a meeting at the White House that he would shrink Food and… Read more »

Bristol Myers cuts guidance on cancer drug issues; shareholders scanning skies for vultures with deep pockets

The News: Bristol-Myers Squibb Co. (New York City) cut its earnings guidance for the year as the drugmaker contends with dimmed prospects for its top cancer drug after major setbacks… Read more »

Bristol-Myers plunges, Merck buoyed on cancer-drug news; is it still dash for cash, or race to nowhere?

The News: Bristol-Myers Squibb Co. (New York City) won’t seek accelerated approval of its immunotherapy drug Opdivo for lung cancer, confirming that Merck & Co. (Kenilworth NJ) will have a huge head start… Read more »